Oncotarget: Trending with Impact & Company News
ABOUT MIKHAILBLAGOSKLONNYONCOTARGET.COM:
Mikhail (Misha) Blagosklonny, M.D., Ph.D. is a founder and Editor-in-Chief at Oncotarget and Aging, an Editor-in-Chief at Oncoscience, and an editor at Genes and Cancer. These four journals are part of the Impact Journals family of scientific publications, based out of Orchard Park, New York. Dr. Blagosklonny graduated with his Doctor of Medicine and Doctorate from First Pavlov State Medical University in St. Petersburg, Russia. He then moved to the United States—where he became well-known for his contributions in cancer and aging research.
Dr. Blagosklonny has published dozens of experimental and theoretical papers focussing on the selective killing of cancer cells with deregulated cell cycle or drug resistance by exploiting their resistance, and other exciting papers on aging.
To read more about Dr. Blagosklonny and his unique work, click here.
For more from Misha himself, follow him on Twitter at @Blagosklonny.
TRENDING WITH IMPACT: Altmetric Scores & Company News
On September 15, 2022, Oncotarget was accepted again for indexing by MEDLINE. Oncotarget is now indexed by Medline/PubMed and PMC/PubMed.
Oncotarget is a primarily oncology-focused, peer-reviewed, open access journal. Papers are published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed. Learn about the six components of the Oncotarget Scientific Integrity process: Presence of Ethics Statements, Adherence to Scientific Publishing Standards, Rigorous and Insightful Peer Review, Elimination of Plagiarism, Image Forensics, and Post-Publication Investigations.
The Trending with Impact series highlights Oncotarget publications that are attracting higher visibility among readers around the world online, in the news, and on social media—beyond normal readership levels. Oncotarget is proud to offer Altmetric scores on papers for readers online. With one click via the Altmetric donut badges to the left of the paper title, you may learn about the recorded original shares and mentions the paper appears in. Oncotarget believes that this level of information available to readers increases journal dependability and trust. A list of publications with an Altmetric score higher than 100 can be found at Oncotarget.com/news/altmetric.
In addition to trending papers, readers may also find Oncotarget company news published on mikhailblagosklonnyoncotarget.com, including the announcement of Special Collections. Look for future science news and articles about the latest trending publications here, at Oncotarget.org, and Oncotarget.com. To hear directly from the distinguished network of authors who continue to publish their research with Oncotarget and learn about our community-based news and events, visit Oncotarget.net.
CONTACT INFORMATION:
For additional information about the Oncotarget Journal, follow us on Twitter @Oncotarget or visit the website.
For media inquiries, please contact media@impactjournals.com.
Oncotarget Journal’s ISSN is 1949-2553 and is indexed and/or archived in PubMed, Scopus, PMC, and the Chan Zuckerberg Meta initiative.
Mikhailblagosklonny.com | Oncotarget.org | Oncotarget.net | Oncotarget.com